Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to NSCLC
Related studies linked through entity extraction aliases.
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
- Status
- COMPLETED
- Phase
- PHASE2
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
- Status
- COMPLETED
- Phase
- N/A
Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study
- Status
- TERMINATED
- Phase
- NA
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC
- Status
- UNKNOWN
- Phase
- N/A
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment
- Status
- COMPLETED
- Phase
- PHASE2
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
- Status
- COMPLETED
- Phase
- N/A
A Study of BCD-135 in Patients With Advanced Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients
- Status
- UNKNOWN
- Phase
- N/A
A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction
- Status
- COMPLETED
- Phase
- PHASE3
Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC
- Status
- UNKNOWN
- Phase
- PHASE3
Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
- Status
- UNKNOWN
- Phase
- PHASE2
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
- Status
- COMPLETED
- Phase
- PHASE2
Intervention of Engineered Immune Effector T Cells Against Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
- Status
- TERMINATED
- Phase
- PHASE2
The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001
- Status
- COMPLETED
- Phase
- PHASE1